Refractive surgery and dry eye.
Leonardo MastropasquaPiero BarboniGiacomo SaviniEmanuela AragonaRossella D'AloisioManuela LanziniLuca AgnifiliAlice GalzignatoAntonio SolimeoKarl Anders KnutssonElisabeth M MessmerPublished in: European journal of ophthalmology (2023)
Refractive surgery is one of the most common elective surgeries performed worldwide. The incidence of dry eye disease (DED) after corneal refractive surgery varies among different studies. Pre-existing untreated DED has been identified as a risk factor for postsurgical dry eye symptoms. On the basis of both evidence and clinical experience, some recommendations for ocular surface and DED management pre- and post-refractive surgery are described. In aqueous deficiency Dry Eye Disease, preservative-free lubricating drops should be preferred, in addition to ointment and gel forms. Topical anti-inflammatory agents (Cyclosporine 0.1%, hydrocortisone phosphate, fluorometholone) should be used for 3-6 months in cases of ocular surface damage. The therapy of evaporative DED includes lifestyle modifications, lid hygiene (either performed by the patient or offered as professional lid hygiene by the physician), use of lubricating eye drops with lipid components, topical and/or systemic antibiotic treatment with anti-inflammatory properties and Intense Pulsed Light (IPL-) Treatment for meibomian gland dysfunction.
Keyphrases
- minimally invasive
- coronary artery bypass
- anti inflammatory
- cataract surgery
- surgical site infection
- wound healing
- primary care
- oxidative stress
- emergency department
- metabolic syndrome
- optical coherence tomography
- percutaneous coronary intervention
- type diabetes
- stem cells
- ionic liquid
- smoking cessation
- clinical practice
- combination therapy
- acute coronary syndrome
- bone marrow
- oral health
- septic shock